On Tuesday, 23 April 2024, the U.S. FDA granted accelerated approval to Day One Biopharmaceuticals for tovorafenib, the first targeted therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). As explained in Day One’s press release, “pLGG is the… Read More
January 2024 – Imaging Endpoints (IE) is a global leader specializing in comprehensive imaging services for clinical trials. Our profound expertise includes analysis of CT, MRI, and PET/SPECT molecular imaging, particularly in the context of gynecologic malignancies, including cervical cancer.… Read More
September is a significant month for many reasons, but in the medical community, it stands out as Childhood Cancer Awareness Month. This month, we spotlight the pressing global health challenge of childhood cancer, which remains one of the leading causes… Read More
March 24, 2023 Abstract Despite a growing number of effective therapeutic options for patients with pancreatic adenocarcinoma, the prognosis remains dismal mostly due to the late-stage presentation and spread of the cancer to other organs. Because a genomic analysis of… Read More
This is an excerpt from our white paper, “Tumor Growth Kinetic Modeling.” To access the full white paper, click here. UNDERSTANDING TUMOR GROWTH KINETICS Estimating the changes in tumor burden that an individual or cohort of patients experience during treatment… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
